Zacks: Analysts Expect Tricida Inc (TCDA) to Post -$0.80 Earnings Per Share

Brokerages predict that Tricida Inc (NASDAQ:TCDA) will post ($0.80) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Tricida’s earnings. The highest EPS estimate is ($0.79) and the lowest is ($0.80). The business is expected to report its next earnings results on Thursday, June 27th.

According to Zacks, analysts expect that Tricida will report full-year earnings of ($3.34) per share for the current financial year, with EPS estimates ranging from ($3.45) to ($3.22). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.34) per share, with EPS estimates ranging from ($3.52) to ($3.15). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Tricida.

Tricida (NASDAQ:TCDA) last announced its earnings results on Thursday, March 28th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.23.

A number of brokerages have recently commented on TCDA. Zacks Investment Research cut shares of Tricida from a “buy” rating to a “hold” rating in a report on Thursday. Empire lifted their price objective on shares of Tricida from $37.00 to $58.00 in a research report on Monday, April 1st.

Shares of Tricida stock traded down $0.09 during trading on Monday, reaching $32.74. The company’s stock had a trading volume of 550,800 shares, compared to its average volume of 339,722. The stock has a market capitalization of $1.40 billion and a price-to-earnings ratio of -7.06. Tricida has a fifty-two week low of $19.43 and a fifty-two week high of $40.83. The company has a debt-to-equity ratio of 0.20, a current ratio of 16.50 and a quick ratio of 16.51.

In related news, insider Gerrit Klaerner sold 8,000 shares of Tricida stock in a transaction on Monday, March 4th. The shares were sold at an average price of $23.92, for a total value of $191,360.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Dawn Parsell Otto sold 2,000 shares of Tricida stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 151,794 shares of company stock worth $4,407,688.

A number of large investors have recently bought and sold shares of TCDA. Wells Fargo & Company MN purchased a new position in Tricida in the 3rd quarter valued at $170,000. Rhumbline Advisers purchased a new stake in shares of Tricida during the 3rd quarter worth $270,000. Bank of New York Mellon Corp purchased a new stake in shares of Tricida during the 3rd quarter worth $1,057,000. BlackRock Inc. boosted its position in shares of Tricida by 216.4% during the 3rd quarter. BlackRock Inc. now owns 1,005,103 shares of the company’s stock worth $30,707,000 after purchasing an additional 687,414 shares in the last quarter. Finally, American International Group Inc. purchased a new stake in shares of Tricida during the 3rd quarter worth $237,000. Hedge funds and other institutional investors own 69.83% of the company’s stock.

Tricida Company Profile

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

Featured Article: Green Investing

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit